SYGNIS AG

EANS-Adhoc: SYGNIS Pharma AG
SYGNIS announces Management Board changes

--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Board of Directors (Appointments and Changes)/C.E.O. Interviews
25.03.2013


SYGNIS announces Management Board changes

Heidelberg, March 25, 2013 - SYGNIS Pharma AG (Frankfurt: LIO1; ISIN:
DE000A1RFM03, Prime Standard), today announced that Chief Financial Officer
(CFO) and member of the Management Board, Peter Willinger will be stepping down
effective 31 March 2013 for personal reasons. He is leaving the company by
mutual agreement with the Supervisory Board. Pilar de la Huerta, the company's
CEO since 2012 and a former senior manager and CFO at Zeltia, S.A., the largest
Spanish quoted biotech company, will now hold both positions, CFO and CEO.

**** end of ad hoc ****


For further information please contact:

SYGNIS Pharma AG                        
Pilar de la Huerta

CEO/CFO                         
Tel: +34-918063089                      
Email: pdelahuerta@sygnis.es                 


### Disclaimer

This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. Some statements included in
this press release, relating neither to proven financial results nor other
historical data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees since given
their very nature they are subject to known and unknown risks and
imponderability and can be affected by other factors as a consequence of which
the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from
the established conclusions or implied predictions contained in such statements.
SYGNIS does not undertake to publicly update or revise these statements in the
light of new information or future results or for any other reason.
###


Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
mail:     contact@sygnis.de
WWW:      http://www.sygnis.de
sector:      Biotechnology
ISIN:        DE000A1RFM03
indexes:     CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
             Stuttgart, regulated dealing/prime standard: Frankfurt 
language:   English
 



Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: